Search hospitals > California > Walnut Creek
John Muir Medical Center-Walnut Creek
Claim this profileWalnut Creek, California 94598
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Adenocarcinoma
Conducts research for Serous Cystadenocarcinoma
Conducts research for Clear Cell Adenocarcinoma
70 reported clinical trials
4 medical researchers
Summary
John Muir Medical Center-Walnut Creek is a medical facility located in Walnut Creek, California. This center is recognized for care of Cancer, Recurrence, Adenocarcinoma, Serous Cystadenocarcinoma, Clear Cell Adenocarcinoma and other specialties. John Muir Medical Center-Walnut Creek is involved with conducting 70 clinical trials across 145 conditions. There are 4 research doctors associated with this hospital, such as Babak Edraki, MD, Gigi Q. Chen, Tiffany H. Svahn, and Marjaneh Moini.Area of expertise
1Cancer
Global LeaderStage II
Stage III
Stage IV
2Recurrence
Global LeaderStage III
Stage IV
BRCA1 positive
Top PIs
Babak Edraki, MDJohn Muir Medical Center-Concord Campus1 year of reported clinical research
Studies Cancer
Studies Ovarian Cancer
8 reported clinical trials
25 drugs studied
Gigi Q. ChenJohn Muir Medical Center-Concord Campus2 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
6 reported clinical trials
14 drugs studied
Tiffany H. SvahnJohn Muir Medical Center-Walnut Creek4 years of reported clinical research
Studies Breast Cancer
Studies Cancer
2 reported clinical trials
5 drugs studied
Marjaneh MoiniJohn Muir Medical Center-Walnut Creek12 years of reported clinical research
Studies Breast Cancer
1 reported clinical trial
1 drug studied
Clinical Trials running at John Muir Medical Center-Walnut Creek
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Prostate Cancer
Cancer
Colorectal Cancer
Squamous Cell Carcinoma
ALK Gene Rearrangement
Prostate Adenocarcinoma
Tumors
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Intraoperative Radiation Therapy
for Breast Cancer
This phase IV trial studies the side effects of intraoperative radiation therapy and how well it works in treating patients with breast cancer undergoing breast-conserving surgery. Delivering radiation one time to the area where the tumor was removed while the patient is still in the operating room may kill any residual tumor cells and may be as effective as standard radiation therapy in patients with early stage breast cancer.
Recruiting1 award N/A2 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at John Muir Medical Center-Walnut Creek?
John Muir Medical Center-Walnut Creek is a medical facility located in Walnut Creek, California. This center is recognized for care of Cancer, Recurrence, Adenocarcinoma, Serous Cystadenocarcinoma, Clear Cell Adenocarcinoma and other specialties. John Muir Medical Center-Walnut Creek is involved with conducting 70 clinical trials across 145 conditions. There are 4 research doctors associated with this hospital, such as Babak Edraki, MD, Gigi Q. Chen, Tiffany H. Svahn, and Marjaneh Moini.